Quantcast

Latest Bristol-Myers Squibb Stories

2014-05-09 20:23:02

Supply of paclitaxel will not be disrupted for Canadian patients OTTAWA, May 9, 2014 /CNW/ - Health Canada today confirmed it has suspended the establishment licence of Biolyse Pharma Corporation's facility in St. Catharines, Ont., because of significant concerns with the manufacturing process discovered during a recent inspection. Injectable paclitaxel (6mg/ml), used in the treatment of certain lung and breast cancers, is currently the only drug produced at that facility....

2014-05-07 23:14:28

Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that Anne Morisseau and Frank Spina of Bristol-Myers Squibb will speak at Pharmica’s SharePoint Conference for the Life Sciences Industry on June 4th and 5th in Plymouth Meeting, PA. Plymouth Meeting, PA (PRWEB) May 07, 2014 As part of its continued service to the industry, Pharmica will host its 10th SharePoint conference in Plymouth Meeting, PA on June 4-5, 2014. The two day...

2014-05-06 16:32:03

OTTAWA, May 6, 2014 /CNW/ - Health Canada today released the April 2014 issue of the Canadian Adverse Reaction Newsletter (CARN). This issue features an article on the risk of a potentially life-threatening condition called drug reaction with eosinophilia and systemic symptoms suspected of being associated with azithromycin, an antibiotic used to treat a variety of infections. It also includes an article on quetiapine, a drug used to treat certain psychiatric disorders, and...

2014-04-30 11:01:45

The risks of birth defects in children exposed to antiretroviral drugs in utero are small when considering the clear benefit of preventing mother-to-child transmission of HIV but where there are safe and effective alternatives, it might be appropriate to avoid use by pregnant women of drugs that may be associated with elevated risks of birth defects, such as zidovudine and efavirenz, according to a study published by French researchers published in this week's PLOS Medicine. The...

2014-04-29 20:23:44

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The World Market for Orphan Drugshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/world_market_orphan_drugs_1.htmlIn recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S.,...

2014-04-29 12:34:11

SAN DIEGO and TAIZHOU CITY, China, April 29, 2014 /PRNewswire/ -- Ambrx Inc. and Zhejiang Hisun Pharmaceutical Company Ltd. (SSE Code: 600267) today announced a collaboration for the development and commercialization of bispecifics based on Ambrx technology for the treatment of cancer. Hisun will have commercial rights to the products in China, while Ambrx will retain commercial rights outside of China and will be entitled to receive royalties on sales of the products in China. Hisun...

2014-04-24 08:34:30

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 24, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited...

2014-04-14 11:03:19

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). "Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of...

2014-04-07 16:25:29

SAN DIEGO, April 7, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of Ian B. Walters, M.D., MBA., a translational oncology and immunology expert. Dr. Walters was most recently an executive at Bristol Myers Squibb (BMS) where he led oncology drug development programs, large international matrix teams, and strategic transactions. He...

2014-04-04 12:27:03

SAN DIEGO, April 4, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq(TM) and Abraxane(®) (nab-paclitaxel) pharmacokinetics (PK) from animal studies. The PK data will be presented by Dr. Kouros Motamed, Vice President of Clinical Development & Nanomedicine on April 9 from 8:00 AM to...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related